Clinical Trial Update: Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer [Phase 2]

View source ↗

Summary

This entry reports on a Phase 2 biomarker study evaluating the combination of sunitinib and docetaxel in castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Sutent (sunitinib)

Snippet

Sponsor: Medical University of Vienna | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: UNKNOWN